Advertisement

Commentary: Moving the Dial on DOAC use Early After Cardiac Surgery

  • Asishana A. Osho
    Affiliations
    Fellow in Cardiothoracic Surgery, Harvard Medical School and Massachusetts General Hospital, Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts
    Search for articles by this author
  • Gus J. Vlahakes
    Correspondence
    Address reprint requests to Gus J. Vlahakes, MD, Division of Cardiac Surgery, Massachusetts General Hospital, 55 Fruit Street, COX630, Boston, MA 02114-2696. Phone: 617-680-0900.
    Affiliations
    Professor of Surgery, Harvard Medical School. Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts
    Search for articles by this author
      Fundamental to the authors’ findings is the important demonstration of the safety of using newer anticoagulants in early postop cardiac surgical patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Megens MR
        • Churilov L
        • Thijs V
        New-onset atrial fibrillation after coronary artery bypass graft and long-term risk of stroke: A meta-analysis.
        J Am Heart Assoc. 2017; 6https://doi.org/10.1161/JAHA.117.007558
        • Gialdini G
        • Nearing K
        • Bhave PD
        • et al.
        Perioperative atrial fibrillation and the long-term risk of ischemic stroke.
        JAMA. 2014; 312: 616-622https://doi.org/10.1001/jama.2014.9143
        • Nauffal V
        • Trinquart L
        • Osho AA
        • et al.
        Non-Vitamin K antagonist oral anticoagulant vs warfarin for post cardiac surgery atrial fibrillation.
        Ann Thorac Surg. 2021; 0https://doi.org/10.1016/j.athoracsur.2020.12.031
        • Siegal DM
        • Curnutte JT
        • Connolly SJ
        • et al.
        Andexanet alfa for the reversal of Factor Xa Inhibitor activity.
        N Engl J Med. 2015; 373: 2413-2424https://doi.org/10.1056/NEJMoa1510991
        • Pollack CV
        • Reilly PA
        • van Ryn J
        • et al.
        Idarucizumab for dabigatran reversal—Full cohort analysis.
        N Engl J Med. 2017; 377: 431-441https://doi.org/10.1056/NEJMoa1707278
        • Granger CB
        • Alexander JH
        • McMurray JJ
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992https://doi.org/10.1056/NEJMoa1107039
        • Patel MR
        • Mahaffey KW
        • Garg J
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891https://doi.org/10.1056/NEJMoa1009638
        • Hage A
        • Dolan DP
        • Nasr VG
        • et al.
        Safety of direct oral anticoagulants compared to warfarin for atrial fibrillation after cardiac surgery: A systemic review and meta-analysis.
        Semin Thorac Cardiovasc Surg. 2022; 34: 947-957
        • Osho AA
        • Moonsamy P
        • Ethridge BR
        • et al.
        Rationale and design of the randomized controlled trial of new oral anticoagulants vs. warfarin for post cardiac surgery atrial fibrillation: The NEW-AF Trial.
        Ann Surg. 2020; (Publish Ahead of Print:440-453)https://doi.org/10.1097/sla.0000000000004459

      Linked Article

      • Safety of Direct Oral Anticoagulants Compared to Warfarin for Atrial Fibrillation after Cardiac Surgery: A Systematic Review and Meta-Analysis
        Seminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
        • Preview
          The evidence for use of direct oral anticoagulants (DOACs) in the management of post-operative cardiac surgery atrial fibrillation is limited and mostly founded on clinical trials that excluded this patient population. We performed a systematic review and meta-analysis of clinical trials and observational studies to evaluate the hypothesis that DOACs are safe compared to warfarin for the anticoagulation of patients with post-operative cardiac surgery atrial fibrillation. We searched PubMed, EMBASE, Web of Science, clinicaltrials.gov, and the Cochrane Library for clinical trials and observational studies comparing DOAC with warfarin in patients ≥18 years old who had post-cardiac surgery atrial fibrillation.
        • Full-Text
        • PDF